Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE – Get Rating) – Equities researchers at Wedbush decreased their FY2026 earnings per share estimates for shares of Ultragenyx Pharmaceutical in a report released on Friday, July 29th. Wedbush analyst L. Chico now expects that the biopharmaceutical company will earn $1.15 per share for the year, down from their previous forecast of $1.17. The consensus estimate for Ultragenyx Pharmaceutical’s current full-year earnings is ($7.21) per share.
Other equities analysts have also recently issued research reports about the company. StockNews.com cut Ultragenyx Pharmaceutical from a “hold” rating to a “sell” rating in a research note on Tuesday, June 21st. Piper Sandler reaffirmed a “maintains” rating on shares of Ultragenyx Pharmaceutical in a research report on Friday. Barclays lowered their target price on Ultragenyx Pharmaceutical from $141.00 to $105.00 in a research note on Friday. Cowen lowered their target price on Ultragenyx Pharmaceutical from $124.00 to $99.00 in a research note on Friday, May 6th. Finally, Stifel Nicolaus decreased their price target on Ultragenyx Pharmaceutical from $176.00 to $142.00 and set a “buy” rating on the stock in a research note on Friday, July 1st. Two equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and seven have given a buy rating to the company’s stock. According to data from MarketBeat.com, Ultragenyx Pharmaceutical presently has a consensus rating of “Hold” and a consensus target price of $108.42.
Ultragenyx Pharmaceutical Trading Up 2.7 %
Ultragenyx Pharmaceutical (NASDAQ:RARE – Get Rating) last issued its earnings results on Thursday, July 28th. The biopharmaceutical company reported ($2.26) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.72) by ($0.54). Ultragenyx Pharmaceutical had a negative return on equity of 49.18% and a negative net margin of 141.65%. The company had revenue of $89.34 million during the quarter, compared to analyst estimates of $87.33 million. During the same period last year, the business earned ($1.45) earnings per share. The firm’s revenue was up 2.7% compared to the same quarter last year.
Institutional Investors Weigh In On Ultragenyx Pharmaceutical
Several institutional investors and hedge funds have recently modified their holdings of the stock. Vanguard Group Inc. boosted its position in shares of Ultragenyx Pharmaceutical by 0.7% in the first quarter. Vanguard Group Inc. now owns 5,963,374 shares of the biopharmaceutical company’s stock worth $433,060,000 after buying an additional 42,806 shares during the period. Wellington Management Group LLP boosted its holdings in Ultragenyx Pharmaceutical by 17.1% in the first quarter. Wellington Management Group LLP now owns 3,370,245 shares of the biopharmaceutical company’s stock valued at $244,747,000 after purchasing an additional 492,842 shares during the last quarter. Clearbridge Investments LLC boosted its holdings in Ultragenyx Pharmaceutical by 3.1% in the first quarter. Clearbridge Investments LLC now owns 2,863,921 shares of the biopharmaceutical company’s stock valued at $207,978,000 after purchasing an additional 85,062 shares during the last quarter. State Street Corp boosted its holdings in Ultragenyx Pharmaceutical by 16.1% in the first quarter. State Street Corp now owns 1,948,684 shares of the biopharmaceutical company’s stock valued at $141,513,000 after purchasing an additional 269,843 shares during the last quarter. Finally, Alliancebernstein L.P. boosted its holdings in Ultragenyx Pharmaceutical by 13.1% in the fourth quarter. Alliancebernstein L.P. now owns 1,308,156 shares of the biopharmaceutical company’s stock valued at $110,003,000 after purchasing an additional 152,002 shares during the last quarter. Hedge funds and other institutional investors own 97.49% of the company’s stock.
Ultragenyx Pharmaceutical Company Profile
Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.
- Get a free copy of the StockNews.com research report on Ultragenyx Pharmaceutical (RARE)
- Use These To Find Your Stock’s Support and Resistance Levels
- Is Boeing Stock is Ready for Lift-Off ?
- Elon Musk is Out, But Should You Be In Twitter Stock?
- 3 Earnings Announcements That Could Surprise
- Twitter’s Up For Third Week In A Row: What’s Next For The Stock?
Want More Great Investing Ideas?
- Bear Market Game Plan!
- The 10 Best Stocks to Own in 2022
- 7 Stocks to Buy and Hold Forever
- 3 Stocks to DOUBLE This Year
Receive News & Ratings for Ultragenyx Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.